Bencao Notes

Why a promising cranberry trial didn’t settle the claim

A cranberry cross-section showing pale flesh, red skin and amber seeds against black, with a 2.5 millimetre scale bar.
Inside a cranberry: Vaccinium macrocarpon, cultivar M34.

Can cranberry help? It sounds like a small question. Ask whether it prevents another urinary infection, treats one happening now, or validates the capsule in your hand, and you have asked three different questions. The answers have not moved together.

That is what makes the recent cranberry story interesting. A favorable trial published in 2025 sits alongside an unfavorable European assessment of a particular product claim. The assessment accepted a positive trial result. Its hesitation concerned whether the evidence, taken together, was sufficiently consistent. Counting headlines for and against the fruit misses that distinction.

A reputation that research has revised

Cranberry has never lacked a story. The challenge has been translating that story into a result people can count. In its 2012 review, Cochrane found insufficient support to recommend cranberry juice for preventing urinary tract infections. The review also described a practical obstacle: people often stopped drinking it. A proposed preventive habit has to survive ordinary life as well as a laboratory explanation.

By the November 2023 update, the evidence base had grown to 50 trials involving 8,857 participants. The conclusion became more favorable for women with recurrent infections. In that subgroup, eight studies with 1,555 participants suggested a relative risk of 0.74 for symptomatic, culture-verified infection, with moderate-certainty evidence.

The review illustrated that result as roughly 24 people in 100 having an infection without cranberry, versus 18 with it: about six fewer. Those are illustrative risks across studies with differing follow-up, not a promise for a particular bottle or person. The confidence interval stretched from a substantial reduction to almost no difference. A useful possibility and uncertainty can occupy the same sentence.

Whole red cranberries and a small gold-colored spoon on a white surface.
Whole cranberries on a white background.

The newer trial, in actual people

A paper published in 2025 by Welma Stonehouse and colleagues reported an Australian trial conducted in 2017–2019. At five sites, 150 otherwise healthy women aged 18–65 with recurrent infections were randomized to a specific 500 mg whole-cranberry powder, Pacran, or a matched soy-oil placebo daily for six months.

The primary analysis included 145 participants. Culture-confirmed infections occurred in 13 of 73 cranberry participants and 25 of 72 placebo participants: 17.8% versus 34.7%, an observed difference of about 17 percentage points. The adjusted relative risk was 0.48, with a 95% confidence interval of 0.26–0.87.

That is encouraging, but slow recruitment stopped enrollment at half the planned 300. Neither the suspected-symptomatic-infection outcome nor the primary outcome in the smaller per-protocol analysis, restricted to participants who followed the protocol, reached statistical significance. Swisse funded CSIRO’s study; the sponsor and ingredient supplier helped design and monitor it. The authors reported no company influence on analysis or reporting. Those details belong next to the result.

Notice the words that tend to disappear when research travels to a shelf: this preparation, these participants, this outcome, this period. Removing them turns a bounded finding into something much larger. Keeping them makes the result more useful, because it shows where a comparison can begin.

The six-person difference in the review and the 17-point difference in this trial are therefore not rival promises. The first illustrates a pooled estimate; the second describes an observed result in one study. Neither tells you what would happen if you switched to another formulation tomorrow. Numbers become easier to interpret when you keep the people and circumstances attached.

Then why did Europe remain unconvinced?

In its 2025 assessment of Pacran, the European Food Safety Authority considered a proposed claim about helping defend the lower urinary tract against bacterial pathogens. It explicitly accepted a beneficial result from a six-month Australian trial of 150 women. The difficulty was that the benefit was not consistently observed in another relevant study. Mechanistic support was also limited. The panel concluded that the submitted evidence did not establish the claimed cause-and-effect relationship.

That assessment concerned a named ingredient and a specific health claim. Whether cranberry can be a prevention option is a broader question. The 2025 AUA/CUA/SUFU guideline advises clinicians to offer cranberry as an option for women with recurrent uncomplicated UTIs, while discussing variability in products and the difficulty of obtaining preparations used in research.

It is possible to take both documents seriously. A clinical option is a choice to discuss in a particular situation. Substantiating a commercial claim is a judgment about a specified body of evidence. Neither document gives every cranberry product the same status. Read the question before treating a verdict as universal.

A large number on the label is not an answer

Proanthocyanidins, usually shortened to PACs, are part of the cranberry discussion. NCCIH explains the proposed anti-adhesion effect: cranberry constituents may make it harder for bacteria to attach to the bladder lining. It also notes that processing can change PAC concentration. A plausible mechanism helps explain what researchers are testing; it does not determine what a capsule will accomplish.

Even the intuitive idea that a higher PAC number must work better has limits. A 2021 randomized trial compared 37 mg with 2 mg daily in 145 women over 24 weeks. The overall reduction in symptomatic infections did not reach statistical significance. The study does not settle every dose question, but it does make a simple “more is better” rule difficult to defend.

For a reader comparing products, the useful move is smaller: identify the actual formulation and daily amount in the study, then ask what is known about the bottle. A berry name on both pages starts the comparison. It does not complete it. Our bottle-to-study guide shows how to make that comparison without pretending the missing information is available.

The question that should stay separate

Prevention is about the next episode. Symptoms now require a different decision. NCCIH advises people who think they have a UTI to seek assessment and not substitute cranberry for proven treatment. Its safety information also notes conflicting evidence about interaction with warfarin. This is one reason a personal medication list matters more than a reassuring picture of fruit.

The interesting change in cranberry is not that uncertainty has vanished. It is that the uncertainty has become more specific. There is a stronger basis for a conversation about recurrence prevention in some women, and a clearer reason to ask which product and which outcome. Bring those questions to the appointment. Let the bottle earn its connection to the evidence.

Sources & what they establish

  1. Jepson and colleagues, Cochrane, 2012. Earlier systematic review; included to show how the conclusion changed, not as the current evidence summary.
  2. Williams and colleagues, Cochrane, November 2023. Systematic review; recurrent-UTI subgroup and illustrative absolute risks. Products and follow-up differed.
  3. Stonehouse and colleagues, AJCN, 2025. Primary randomized trial; Table 2 supplies the event counts. One whole-fruit preparation; industry sponsorship is disclosed.
  4. EFSA NDA Panel, Pacran assessment, 2025. Official assessment of a product-specific claim; not a judgment on all cranberry preparations.
  5. AUA/CUA/SUFU recurrent-UTI guideline, amended 2025. Clinical guidance for recurrent uncomplicated infections in women; statement 13 addresses cranberry as a prevention option.
  6. Babar and colleagues, BMC Urology, 2021. Primary randomized dose comparison; the overall result does not establish a higher-dose advantage.
  7. NCCIH cranberry fact sheet, updated November 2024. Official context on proposed mechanisms, treatment limits, and safety; not an endorsement of a product.

Published by Bencao Notes Sources checked: 2026-09-30

Review status

Editorial demonstration · Independent clinical review pending

Named author and reviewer credentials have not yet been provided. Source verification is not clinical review. Editorial standards and disclosures

← Back to the collectionSources, standards & disclosures

Image credits